Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma 4Stomach Neoplasms 3Ovarian Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1Ascites 1

Interventions

catumaxomab 1Paracentesis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) × catumaxomab × Clear all
NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Neovii Biotech

Phase 2/3 Completed
258 enrolled
BreastGastrointestinalGynecologic

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡